Is there any advantage to the rapid replacement of CAR-T in cell therapy technology?

Author: forest

In recent years, immunotherapy, as an emerging tumor treatment method, has become a hot spot in the research of malignant tumor treatment

Up to now, a total of 7 CAR-T products have been launched in the world, including 2 domestic models, from Fosun Kite and WuXi Junuo.

Data source: Yaozhi Data

Although the high treatment cost of CAR-T therapy is daunting, its breakthrough therapeutic effect also gives people hope and attracts many domestic and foreign companies to invest in it

This year, the 63rd annual meeting of the American Society of Hematology (ASH) will be held in the United States from December 11 to 14 in an offline and online format

Source: ASH

Second-line treatment of lymphoma, Gilead, BMS seize the opportunity

Currently, companies are working hard to advance CAR-T therapy to earlier oncology treatments

Previously, Bristol-Myers Squibb reported that TRANSFORM had met its primary endpoint of EFS, as well as secondary goals of complete response rate (CR) and progression-free survival (PFS)

It is also worth noting that Breyanzi was only approved for marketing in February this year for the treatment of adult patients with relapsed/refractory LBCL who have received two or more systemic treatments, and its unique feature is that CD8-positive and CD8-positive CAR-T therapy The proportion of CD4-positive T cells can be controlled, which allows better control of the toxic side effects of cell therapy; Breyanzi (lisocabtagene maraleucel) in the phase 3 clinical trial primary endpoint and key secondary endpoint results show significant improvement compared to standard treatment Event-free survival, complete response rate, and progression-free survival in patients with relapsed/refractory large B-cell lymphoma (LBCL)

However, Novartis had less luck

However, this year Novartis will announce early clinical results for two other CAR-Ts, CD19-targeting YTB323 and BCMA-targeting PHE885

A variety of domestic CAR-T will be unveiled at the ASH annual meeting

Johnson & Johnson/Legend Bio will present the CARTITUDE series of studies at the 2021 ASH Annual Meeting (BCMA-targeted CAR-T therapy - cilta-cel for the treatment of patients with relapsed or refractory multiple myeloma) update data

In addition, Legend Bio will share the preclinical in vivo data of a novel trispecific single-domain antibody (VHH) CAR-T (LCAR-AIO) for the first time

In addition to cilta-cel, Keji Bio's BCMA CAR-T and Gracell's CD19/CD7 dual-targeting CAR-T will also appear at this year's ASH annual meeting

Keji Pharmaceutical will publish the latest research data of CT053 in the form of a poster at this year's ASH annual meeting

Gracell will present the preclinical study data of its CAR-T cell therapy candidate GC502 in the treatment of B-cell malignancies at the conference in the form of an electronic poster

Universal cell therapy takes the stage

In addition to autologous CAR-T, more cutting-edge cell therapy programs will be unveiled at this ASH annual meeting.

PBCAR0191 is a universal allogeneic CD19-targeted CAR-T cell therapy developed by Precision in collaboration with Servier.

ALLO-501, an anti-CD19 allogeneic CAR-T therapy developed by Allogene, achieved 75% ORR and 50% CR in a Phase I trial of ALL-501 for relapsed/refractory large B-cell lymphoma
.

In addition, Fate's CAR-NK project FT596 has also attracted much attention
.
FT596 is the first cell-based immunotherapy product based on natural killer (NK) cells on sale, and the first cell-based immunotherapy product that has been genetically engineered to include three active anti-tumor components
.
At ASH 2019, Fate reported a preclinical study of FT596, confirming that cellular immunotherapy for B-cell tumors may eventually become an off-the-shelf product that can be mass-produced uniformly
.
More data will be released this year
.

Companies such as Fate are also developing universal cell therapies based on the differentiation of iPSC cells
.
In addition, multi-target cell therapy has also shown advantages
.

At present, we do not know much about cell therapy, and in the future, cell therapy will certainly be different
.
The development of science is endless, the problems that are plaguing us now may be solved in the future, and the "cure" of blood tumors will also become a reality
.

Reference source

1.
https:// https://